Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name SBI-0206965
Trade Name
Drug Descriptions

SBI-0206965 is a small molecule that selectively inhibits ULK1, resulting in decreased phosphorylation of ULK1 targets, and potentially leading to increased tumor cell death in combination with mTOR inhibitors (PMID: 26118643, PMID: 30166400, PMID: 32393312).

CAS Registry Number 1884220-36-3


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
AZD8055 + SBI-0206965 AZD8055 SBI-0206965 0 0
Cabozantinib + SBI-0206965 Cabozantinib SBI-0206965 0 0
Crizotinib + SBI-0206965 Crizotinib SBI-0206965 0 0
Regorafenib + SBI-0206965 Regorafenib SBI-0206965 0 0
Sapanisertib + SBI-0206965 SBI-0206965 Sapanisertib 0 0
SBI-0206965 SBI-0206965 0 0
SBI-0206965 + Sirolimus SBI-0206965 Sirolimus 0 0

Additional content available in CKB BOOST